1. Introduction {#sec0001}
===============

Osteosarcoma (OS) is the most common pediatric bone cancer with the 5-year survival rate estimated to range from 40% to 75% [@bib0001]. Over 30% of OS patients may finally experience distant metastases and a poor prognosis [@bib0002]. Although the genetic background of OS has been extensively studied, the molecular mechanisms underlying the initiation and progression of OS remains poorly understood. Therefore, investigations on the molecular etiology of OS are essential to improve the treatment of this devastating disease.

The functional role of long non-coding RNA (lncRNAs) in the biological activity of malignant tumor has been widely investigated [@bib0003], [@bib0004]. By regulating the expression of target gene through different mechanisms, lncRNAs have been reported to be associated the growth and metastasis of a variety of cancer [@bib0005], [@bib0006], [@bib0007]. Aberrant upregulation of oncogenic lncRNA TUG1 was observed in B-cell malignancies, bladder cancer, hepatocellular carcinoma and OS [@bib0008]. The role of lncRNA CCAT1 has been well documented in OS, gastric cancer (GC), colorectal cancer and hepatocellular carcinoma [@bib0009]. Recently, the growth arrest specific transcript 5 (GAS5) was identified as a tumor-suppressor, including breast cancer, gastric cancer, colorectal cancer and bladder cancer [@bib0010], [@bib0011], [@bib0012], [@bib0013]. Ye et al reported that overexpression of GAS5 may suppress cell growth and EMT of OS through the miR-221/ARHI pathway [@bib0014]. However, the regulatory mechanism underlying down-expressed GAS5 in OS tissues remains poorly understood.

The polymorphism rs145204276 in the promoter region of GAS5 may regulate its expression level by influencing the methylation status [@bib0015]. Tao et al. [@bib0015] reported that the allele del of rs145204276 could regulate the expression of GAS5 and thus increased the risk of hepatocellular carcinoma. Zheng et al.\[10\] observed that the allele del of rs145204276 was associated with a decreased risk of colorectal cancer. To our knowledge, however, there is a paucity of knowledge concerning the association between rs145204276 and the expression of GAS5 in OS. The objective of the current study was to investigate the role of rs145204276 in the development of OS.

2. Methods {#sec0002}
==========

2.1. Subjects {#sec0003}
-------------

The current study was approved by the local institutional review board. A total of 132 OS patients who came to our clinic center for treatment between 2006 January and 2017 March were included. The diagnosis of OS was validated by a multiple disciplinary team composed of a senior orthopedic surgeon, a radiological specialist and a pathologist. Patients received no previous medical treatment before the surgery. 1270 healthy controls were recruited during physical exanimations. Demographic data of the patients were collected from the medical record, including age, gender, tumor size, histological differentiation, Anneking Stage, and presence of distant metastasis. Written informed consent was obtained from all the subjects for the collection of blood or tissue samples.

2.2. Genotyping assay {#sec0004}
---------------------

The genomic DNA was extracted from peripheral blood of each subject using genomic DNA purification kit (Qiagen, Tokyo). DNA fragments containing rs145204276 were amplified using the following primers: F-TCCCGACTGAGGAGGAAGAGCA; R-AACACCGTCCCGGAAGTGAAA as previously reported [@bib0015]. The PCR products were then analyzed by 7% non-denaturing polyacrylamide gel electrophoresis, and the results were visualized by silver staining. The genotype was classified as del/del, del/ins or ins/ins for each patient. 10% samples were randomly sequenced for duplication analysis, which yielded a concordance rate of 100%.

2.3. Expression of GAS in tissues of the patients {#sec0005}
-------------------------------------------------

The tumor tissues and the adjacent normal tissue were collected from 42 patients during surgery. The tissues were stored at −80 °C, and total RNA was extracted with a commercial kit (CWBio. Co. Ltd). The relative expression of GAS5 was quantified by Real-time PCR (RT-PCR) on Roche Light Cycler 480 system with the following primer 5′- CTTCTGGGCTCAAGTGATCCT-3′ and 5′- TTGTGCCATGAGACTCCATCAG-3′. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. The primer for GAPDH designed as 5′-GTCAACGGATTTGGTCTGTATT-3′ and 5′-AGTCTTCTGGGTGGCAGTGAT-3′. The amplification procedures were composed of an initial denaturation step of 95 °C for 10 min, 40 amplification cycles at 95 °C for 10 s, annealing at 60 °C for 20 s and elongation at 72 °C for 10 s. The relative expression of GAS5 was normalized using the ΔΔCt method as previously reported [@bib0015].

2.4. DNA methylation analysis {#sec0006}
-----------------------------

Promoter methylation level of GAS5 was determined using quantitative bisulfite pyrosequencing by the EpigenDx Inc. (Worcester, MA, USA). The target sequence of the 7th CpG site in GAS5 promoter region was listed in [Table 1](#tbl0001){ref-type="table"}. The bisulfite conversion was carried out with 100 ng extracted DNA using the EpiTect Bisulfite Kit (QIAGEN) according to the manufacturer\'s protocol. The converted DNA was then amplified using PyroMark PCR Kit (QIAGEN) with primers mentioned above. The methylation status of each CpG site was analyzed as artificial T/C SNP using QCpG software (Qiagen Pyrosequencing). Each pyrosequencing assay was performed a minimum of three times. DNA methylation analysis was subsequently conducted using the Sequenom EpiTYPER system (Sequenom Inc., USA) as described previously.Table 1Primers sequences and selected CpG sites in the promoter region.Table 1Primer nameSequencesGAS5-p15′-AATATAGTTTAGGAAGTGAAATTTT-3′GAS5-p25′-GTTTTTTTTTTTTTTATTTTTAGA-3′GAS5-p35′-TTTTAGTAGGGAGGAG-3′CpG siteCCACCCCCTCCCACGGAGCGGGCGACGTGCCGGAAGGAAA TCACTCAGCCTTACACCGCCCCCCCTTCCCCCATCCCCA GAGCTTTCCTTGCCT[C]{.ul}GCGCCCCCTCCCCTCTCTGCTCTT CCTCCTCAGTCGGGAGGAGGGCGGGAGCACGGCATCACGTGGACGGTCATGTCTCTGCCCACAATGGCG

2.5. Statistical analyses {#sec0007}
-------------------------

SPSS version 19.0 (SPSS Inc., Chicago, USA) was used for the data analysis. The Hardy-Weinberg equilibrium (HWE) test was performed for all the subjects. The Student\'s t test was used to analyze the continuous date and the Chi-square test was used to analyze the categorical data. Odds ratio (OR) was calculated to evaluate the contribution of rs145204276 to the risk of OS. The effect size (ϕ) was defined as the value of the square root of the Chi square value divided by total number of subjects. Specifically, a ϕ value of 0.1 was defined as small effect, 0.3 as medium effect and 0.5 as large effect. The gene expression and the percentage of methylation alleles were compared among different genotypes of rs145204276 with One-way ANOVA test. The relationship between the gene expression level and the percentage of methylation was determined by Pearson correlation analysis. The statistical significance was set at p \< 0.05.

3. Results {#sec0008}
==========

3.1. Demographic data {#sec0009}
---------------------

As shown in [Table 2](#tbl0002){ref-type="table"}, there was no significant difference between the cases and the controls in terms of age and gender. For the subjects included in the genotyping analysis, the mean age was 31.3 ± 18.4 years for the patients and 30.8 ± 12.3 years for the controls, respectively. Clinical features of the patients, including tumor size, histological differentiation, Enneking Stage and presence of distant metastasis, were summarized in [Table 2](#tbl0002){ref-type="table"}.Table 2Baseline characteristics of the patients and the controls.Table 2FeaturesPatients (n = 132)Controls (n = 1270)pGender0.76Male76748female56522Age (years)0.83 \> 2058546 ≤ 2074724Enneking stagesN/AI19--IIA22--IIB44--III13--Histologic typeN/AOsteoblastic75--Chondroblastic37--Fibroblastic5Mixed15Tumor size (cm)N/A \> 591-- ≤ 541--Tumor metastasisN/APresence45--Absence87--

3.2. Association of rs145204276 with the susceptibility of oS {#sec0010}
-------------------------------------------------------------

The frequency of rs145204276 of the cases and the controls were summarized in [Table 3](#tbl0003){ref-type="table"}. HWE test indicated no selection bias for either group (p \> 0.05). Compared with the controls, patients were found to have significantly lower rate of genotype del/del (7.6% vs. 8.7%, p = 0.024). The frequency of allele del was significantly lower in the patients than in the controls (23.5% vs. 30.1%, p = 0.021), with an OR of 0.72 (95% CI = 0.54--0.97). The effect size (ϕ) of rs145204276 was 0.07.Table 3Comparison of the genotype and allele frequency of rs145204276 between the patients and controls.Table 3GenotypepAllelepOdds ratio (95% CI ^a^)del/deldel/insins/insdelinsPatients (n = 132)10 (7.6%)42 (31.8%)80 (60.6%)0.02462 (23.5%)204 (76.5%)0.0210.72 (0.54--0.97)Controls (n = 1270)111 (8.7%)543 (42.8%)616 (48.5%)765 (30.1%)1775 (69.9%)

3.3. The relationship between rs145204276 and progression and metastasis of oS {#sec0011}
------------------------------------------------------------------------------

The tumor size was compared among different genotypes to determine the relationship between rs145204276 and the progression of OS. As shown in [Table 4](#tbl0004){ref-type="table"}, the tumor size of patients with genotype del/del were remarkably smaller than that of patients with genotype ins/ins (4.1 cm ± 1.7 cm vs. 5.9 cm ± 2.4 cm, p = 0.04).Table 4Comparison of tumor size and metastasis among different genotypes of rs145204276.Table 4Genotypepdel/deldel/insins/insTumor size (cm)4.1 ± 1.75.6 ± 1.95.9 ± 2.40.04Distant metastasis0.19Yes (n = 45)31131No (n = 87)73149

The incidence of distant metastasis was also compared among different genotypes to determine whether rs145204276 is associated with the metastasis of OS. As shown in [Table 4](#tbl0004){ref-type="table"}, patients with genotype del/del had a numerically lower but statistically similar rate of distant metastasis of OS than those with ins/ins (30.0% vs. 38.7% p = 0.19).

3.4. Expression of GAS5 in OS tissues {#sec0012}
-------------------------------------

The relative mRNA expression of GAS5 was significantly lower in the tumor tissue than in the adjacent normal tissues (0.0021 ± 0.0012 vs. 0.0039 ± 0.0022, p \< 0.001). As shown in [Fig. 1](#fig0001){ref-type="fig"}a, patients with different genotypes of rs145204276 were found to have significantly different GAS5 expression. Compared with patients with genotype ins/ins, those with genotype del/del had remarkably higher relative expression of GAS5 (0.0033 ± 0.0019 vs. 0.0018 ± 0.0006, p \< 0.001).Fig. 1Comparison of the gene expression and the percentage of methylation among different genotypes of rs145204276. (a) Patients with genotype del/del had remarkably higher expression of GAS5 than those with genotype ins/ins (0.0033 ± 0.0019 vs. 0.0018 ± 0.0006, p \< 0.001). (b) Patients with genotype del/del had obviously hypermethylation as compared with those with genotype ins/ins (38.7% ± 21.1% vs. 20.5% ± 8.2%, p \< 0.001).Fig 1

3.5. Methylation status of GAS5 {#sec0013}
-------------------------------

As shown in [Fig. 1](#fig0001){ref-type="fig"}b, there was significant difference of methylation percentage in the 7th CpG site. Patients with genotype del/del were found to have obviously hypermethylation as compared with those with genotype ins/ins (38.7% ± 21.1% vs. 20.5% ± 8.2%, p \< 0.001). In addition, the methylation percentage was significantly correlated with the expression of GAS5 (r = 0.364, p = 0.02).

4. Discussion {#sec0014}
=============

With the development of sequencing technology, it was revealed that protein-coding sequences only occupy a small proportion of the whole human genome [@bib0016]. Increasing evidence showed that lncRNAs could be involved in cellular processes of human cancer [@bib0005], [@bib0006], [@bib0007]. In previous studies, a number of lncRNAs have been found to participate in the development and progression of OS [@bib0017], [@bib0018], [@bib0019]. Zhao et al [@bib0020] observed that CCAT1 was upregulated in OS tissues and involved in the proliferation and migration of the cancer cells. As a rising star of tumor-suppressors, the abnormal expression of GAS5 has recently been reported to play a role in a variety of human cancer including OS [@bib0012], [@bib0014], [@bib0015]. For the first time, we systematically investigated the regulatory capacity of the genetic variant on the expression of GAS5 in OS tissues and further evaluated its association with the susceptibility of OS. We found that the allele del of rs145204276 was significantly associated with a decreased risk of OS. Mover, patients with genotype del/del had significantly higher expression of GAS5 in the OS tissues. Apparently, the up-regulation of GAS5 and presence of genotype del/del could play a protective role in the development of OS. It was noteworthy that a ϕ value of 0.07 indicated a small effect of this variant on the development of OS, which was in line with an odds ratio of 0.72. Generally, common variants have a small effect in the development of complex disease, and can only explain a limited proportion of the overall variance. Herein, more factors need to be identified to better clarify the etiology of OS.

In the current study, we investigated the association of rs145204276 with the progression of OS and found it was significantly associated with tumor size. It has been well documented that GAS5 could function as a suppressor of cancer cells and inhibit cell proliferation and migration through different molecular mechanisms [@bib0011], [@bib0012], [@bib0014], [@bib0015]. Guo et al [@bib0021] reported that GAS5 could suppress the transition of G1/S phase of GC cells by up-regulation of P21 and suppression of CDK6. Liu et al [@bib0011] found that GAS5 could act as a ceRNA in GC and suppress the negative regulation of miR-23a. In a recent study, GAS5 was reported to function as a competing endogenous RNA for miR-221 and suppress cell growth of OS by regulating the miR-221/ARHI pathway [@bib0014]. To summarize, the definite mechanism underlying the regulatory effect of GAS5 on the development and progression of human cancer remains obscure. Further investigations are warranted to determine whether GAS5 can serve as a potential therapeutic target for OS.

Located in the promoter region of GAS5, allele del of rs145204276 could result in an increased expression of GAS5 in colorectal cancer and hepatocellular carcinoma [@bib0010], [@bib0015]. Through luciferase activity analysis, Tao et al. [@bib0015] found that rs145204276 could affect the transcriptional activity of GAS5. The authors speculated that rs145204276 could possibly regulate GAS5 expression through the methylation of CpG islands in the promoter region [@bib0015]. In this study, we confirmed that genotype del/del of rs145204276 was associated with a remarkably higher rate of methylation in the 7th CpG site of GAS5 promoter. Moreover, the methylation percentage was significantly correlated with the mRNA expression level of GAS5 in OS tissues. Therefore, it is most likely that rs145204276 played a functional role in the development and progression of OS by altering the methylation status of GAS5 promoter.

There were two limitations in this study that should be addressed. First, the sample size of the OS patients included in the genotyping analysis was relatively small due to a rare incidence of this type of cancer. In the future multi-center study, more OS patients need to be recruited for a stronger statistical power. Second, the mechanism underlying the influence of rs145204276 on methylation status of the GAS5 promoter remains undetermined, which is worthy of further investigation in the future study.

5. Conclusions {#sec0015}
==============

The genetic variant rs145204276 is functionally associated with the susceptibility of OS, which may function as a protective factor in the incidence of OS possibly via regulation of GAS5. The mechanism underlying the influence of rs145204276 on methylation status of the GAS5 promoter needs to be further investigated.
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